<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02280616</url>
  </required_header>
  <id_info>
    <org_study_id>BUU-2/EEA</org_study_id>
    <secondary_id>2009-016692-29</secondary_id>
    <nct_id>NCT02280616</nct_id>
  </id_info>
  <brief_title>Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis</brief_title>
  <official_title>Double-blind, Double-dummy, Randomized, Placebo-controlled, Phase IIa Study on the Efficacy and Tolerability of a 14-day Treatment With Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Patients With Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of a low and high dose of a budesonide
      effervescent tablet and oral viscous budesonide suspension vs. placebo for the induction
      treatment of active eosinophilic esophagitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of histological remission</measure>
    <time_frame>2 weeks (LOCF)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the mean numbers of eos</measure>
    <time_frame>2 weeks (LOCF)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the mean numbers of eos</measure>
    <time_frame>2 weeks (LOCF)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Low dose budesonide tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose budesonide tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose budesonide suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose budesonide tablet</intervention_name>
    <description>1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily</description>
    <arm_group_label>Low dose budesonide tablet</arm_group_label>
    <other_name>BET 1mg BID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose budesonide tablet</intervention_name>
    <description>2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily</description>
    <arm_group_label>High dose budesonide tablet</arm_group_label>
    <other_name>BET 2mg BID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose budesonide suspension</intervention_name>
    <description>placebo tablet twice daily AND 5ml [0.4mg budesonide/ml] suspension twice daily</description>
    <arm_group_label>High dose budesonide suspension</arm_group_label>
    <other_name>BVS 2mg BID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablet twice daily AND 5ml placebo suspension twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Signed informed consent

          -  Male or female patients, 18 to 75 years of age

          -  Confirmed clinicopathological diagnosis of EoE according to established diagnostic
             criteria:

        (A) Clinical symptoms of esophageal dysfunction (B) Peak eosinophils ≥ 15 in at least 1
        high-power field (hpf)

        - Active symptomatic and histological EoE at baseline

        Major Exclusion Criteria:

          -  Clinically and endoscopically suspicion for gastroesophageal reflux disease,
             achalasia, or sklerodermia

          -  Gastroesophageal reflux disease and PPI-responsive esophageal eosinophilia

          -  Other clinical evident causes than EoE for esophageal eosinophilia

          -  Any concomitant esophageal disease and relevant gastro-intestinal disease (celiac
             disease, inflammatory bowel disease, oropharyngeal or esophageal bacterial, viral, or
             fungal infection)

          -  Any relevant systemic disease (e.g., AIDS, active tuberculosis)

          -  Abnormal hepatic function at screening visit, liver cirrhosis, or portal hypertension

          -  Abnormal renal function at screening

          -  History of cancer in the last five years (except for non-metastatic cancers, e.g.,
             basalioma)

          -  History of esophageal surgery at any time or of esophageal dilation procedures within
             the last 8 weeks prior to screening visit

          -  Upper gastrointestinal bleeding within 8 weeks prior to screening visit

          -  Concomitant, or within the 4 weeks prior to screening visit, treatment with systemic
             therapies for any reason that may affect assessment of primary and secondary
             endpoints, i.e., systemic glucocorticoids, histamine antagonists, mast cell
             stabilizers, leukotriene receptor antagonists, biologics, or immunosuppressants

          -  Concomitant, or within the 2 weeks prior to screening visit, treatment with topical
             therapies for any reason that may affect assessment of primary and secondary
             endpoints, i.e., topical glucocorticoids or inhaled sodium cromoglycate

          -  Installation of dietary restrictions within 4 weeks prior to screening visit or during
             treatment

          -  Intake of grapefruit containing food or beverages during the treatment with study
             medication

          -  Known intolerance/hypersensitivity to study drug

          -  Existing or intended pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Mueller, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Falk Pharma GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Digestive Diseases Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Miehlke S, Hruz P, Vieth M, Bussmann C, von Arnim U, Bajbouj M, Schlag C, Madisch A, Fibbe C, Wittenburg H, Allescher HD, Reinshagen M, Schubert S, Tack J, Müller M, Krummenerl P, Arts J, Mueller R, Dilger K, Greinwald R, Straumann A. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut. 2016 Mar;65(3):390-9. doi: 10.1136/gutjnl-2014-308815. Epub 2015 Mar 19.</citation>
    <PMID>25792708</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

